Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

NCT05993442 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3080

Last updated 2026-03-25

No results posted yet for this study

Summary

NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase, and a staggered randomisation approach. The primary focus of the NeoDeco study is on high-risk preterm infants born at less than 32 weeks' gestational age, a population particularly vulnerable to hospital-acquired infections and sepsis during their initial hospital stay. By investigating hospital-acquired infections specifically, the study targets the period during which optimised KC practices are likely to have the most significant impact.

Conditions

  • Infection, Bacterial
  • Infection Prevention

Interventions

BEHAVIORAL

Optimised kangaroo care

The intervention of optimised KC implementation consists of two components. Component 1 defines the targeted StSC for optimised KC, while component 2 is the implementation support to put in place a tailored implementation strategy.,

Sponsors & Collaborators

  • European Clinical Research Alliance for Infectious Diseases (ECRAID)

    collaborator OTHER
  • University of Zurich

    collaborator OTHER
  • Universiteit Antwerpen

    collaborator OTHER
  • Charite University, Berlin, Germany

    collaborator OTHER
  • UMC Utrecht

    collaborator OTHER
  • Swiss Tropical & Public Health Institute

    collaborator OTHER
  • St George's, University of London

    collaborator OTHER
  • PENTA Foundation

    lead NETWORK

Principal Investigators

  • Julia Bielicki, PhD · St George's, University of London

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
32 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-28
Primary Completion
2026-04-30
Completion
2026-05-31

Countries

  • Greece
  • Italy
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05993442 on ClinicalTrials.gov